PYX Resources: Achieving volume and diversification milestones. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksGlaxosmithkline Share News (GSK)

Share Price Information for Glaxosmithkline (GSK)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 1,775.00
Bid: 1,771.00
Ask: 1,771.50
Change: -8.50 (-0.48%)
Spread: 0.50 (0.028%)
Open: 1,773.50
High: 1,779.00
Low: 1,764.50
Prev. Close: 1,783.50
GSK Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

LONDON BROKER RATINGS: HSBC downgrades commercial property stocks

Mon, 10th Jul 2023 09:27

(Alliance News) - The following London-listed shares received analyst recommendations Monday morning and Friday:

----------

FTSE 100

----------

Numis cuts InterContinental Hotels to 'hold' - price target 5,600 pence

----------

Deutsche Bank raises Shell price target to 3,268 (2,907) pence - 'buy'

----------

Citigroup cuts Antofagasta price target to 1,500 (1,600) pence - 'neutral'

----------

Barclays cuts Endeavour Mining price target to 2,600 (3,000) pence - 'overweight'

----------

Barclays cuts Antofagasta price target to 1,270 (1,350) pence - 'equal weight'

----------

Barclays cuts Anglo American price target to 3,100 (3,300) pence - 'overweight'

----------

Citigroup cuts Anglo American price target to 3,000 (3,300) pence - 'buy'

----------

Barclays cuts Fresnillo price target to 525 (630) pence - 'equal weight'

----------

Barclays cuts Rio Tinto price target to 6,400 (6,700) pence - 'equal weight'

----------

Barclays cuts Ocado price target to 640 (740) pence - 'equal weight'

----------

Deutsche Bank raises Coca-Cola HBC target to 3,150 (2,950) pence - 'buy'

----------

Citigroup raises Coca-Cola HBC price target to 2,525 (2,425) pence - 'neutral'

----------

Citigroup cuts Vodafone price target to 73 (83) pence - 'neutral'

----------

Deutsche Bank cuts Weir Group target to 2,100 (2,135) pence - 'hold'

----------

HSBC cuts Segro to 'hold' - price target 608 pence

----------

HSBC cuts Land Securities to 'hold' - price target 485 pence

----------

Morgan Stanley cuts GSK price target to 1,440 (1,485) pence - 'equal-weight'

----------

FTSE 250

----------

HSBC cuts Safestore to 'hold' - price target 770 pence

----------

HSBC cuts Hammerson to 'reduce' - price target 12 pence

----------

HSBC cuts British Land to 'reduce' - price target 233 pence

----------

HSBC cuts Shaftesbury Capital to 'hold' - price target 121 pence

----------

HSBC cuts Great Portland Estates to 'hold' - price target 424 pence

----------

HSBC cuts Big Yellow Group to 'hold' - price target 903 pence

----------

HSBC cuts Derwent London to 'hold' - price target 2144 pence

----------

HSBC cuts Assura Group to 'hold' - price target 49 pence

----------

HSBC cuts Primary Health Properties to 'hold' - price target 102.10 pence

----------

Jefferies cuts Diversified Energy price target to 100 (110) pence - 'hold'

----------

Jefferies raises Ithaca Energy price target to 200 (195) pence - 'buy'

----------

Jefferies cuts Energean price target to 1,100 (1,215) pence - 'hold'

----------

Jefferies cuts Harbour Energy price target to 340 (360) pence - 'buy'

----------

Citigroup raises Morgan Advanced Materials target to 435 (425) pence - 'buy'

----------

RBC cuts IWG price target to 155 (190) pence - 'sector perform'

----------

RBC cuts Currys price target to 60 (70) pence - 'sector perform'

----------

Jefferies cuts Petershill Partners price target to 250 (270) pence - 'buy'

----------

JPMorgan raises Future price target to 1,900 (1,845) pence - 'overweight'

----------

JPMorgan places Ryanair and Wizz Air on 'positive catalyst watch'

----------

SMALL CAP

----------

Panmure raises IQE to 'buy' - price target 40 pence

----------

Barclays raises Wise price target to 675 (620) pence - 'equal weight'

----------

Barclays cuts South32 price target to 195 (200) pence - 'underweight'

----------

Barclays cuts Gem Diamonds price target to 24 (30) pence - 'overweight'

----------

Barclays raises BHP Group price target to 2,715 (2,625) pence - 'equal weight'

----------

Barclays reinitiates Alfa Financial Software with 'overweight' - price target 215 pence

----------

Jefferies cuts Pharos Energy price target to 26 (29) pence - 'buy'

----------

Jefferies cuts Kosmos Energy price target to 660 (750) pence - 'buy'

----------

Jefferies cuts Serica Energy price target to 290 (325) pence - 'buy'

----------

Jefferies raises Jadestone Energy price target to 54 (50) pence - 'buy'

----------

Jefferies raises EnQuest to 'buy' (hold) - price target 20 pence

----------

Jefferies raises Capricorn Energy to 'buy' (hold) - price target 225 (230) pence

----------

Copyright 2023 Alliance News Ltd. All Rights Reserved.

More News
3 Apr 2024 22:01

Biden, Senator Bernie Sanders push companies to cut cost of asthma inhalers, prescription drugs

WASHINGTON, April 3 (Reuters) - President Joe Biden hosted a White House event with U.S. Senator Bernie Sanders on Wednesday to tout their fight against high prescription drug prices and push companies to cut the cost of inhalers for asthma sufferers.

Read more
3 Apr 2024 21:37

What to know about bird flu in dairy cows and the risk to humans

CHICAGO, April 3 (Reuters) - Texas officials reported on Monday that a farm worker tested positive for H5N1, or bird flu, that has spread to dairy cows in Texas, Kansas, New Mexico, Michigan and Idaho - the first time the virus has infected cattle.

Read more
19 Mar 2024 09:21

LONDON BROKER RATINGS: Investec cuts ConvaTec; RBC raises Vistry

(Alliance News) - The following London-listed shares received analyst recommendations Tuesday morning:

Read more
18 Mar 2024 12:00

GSK unveils promising results from endometrial cancer trial

(Sharecast News) - GSK unveiled promising outcomes from a phase three trial of 'Jemperli', or dostarlimab, in treating primary advanced or recurrent endometrial cancer on Monday.

Read more
18 Mar 2024 08:47

TOP NEWS: Pfizer launches GBP2 billion sale of 8% stake in Haleon

(Alliance News) - Haleon PLC on Monday said Pfizer Inc plans to sell around GBP2 billion in Haleon shares, some of which will be bought back by Haleon.

Read more
18 Mar 2024 08:47

GSK says Jemperli combination gets good results for endometrial cancer

(Alliance News) - GSK PLC on Monday said a test of its Jemperli drug in combination with chemotherapy has shown it reduced the risk of death in patients with endometrial cancer by nearly a third.

Read more
7 Mar 2024 09:38

GSK observes positive data in Blenrep trial for blood cancer treatment

(Alliance News) - GSK PLC on Thursday announced positive results for Blenrep for the treatment of multiple myeloma.

Read more
7 Mar 2024 07:21

GSK reports more encouraging trial results for Blenrep

(Sharecast News) - GSK unveiled encouraging results from its 'DREAMM-8' phase three trial on Thursday, comparing the efficacy of 'Blenrep', or belantamab mafodotin, in combination with pomalidomide plus dexamethasone, or PomDex, against the standard treatment of bortezomib plus PomDex in relapsed or refractory multiple myeloma patients.

Read more
5 Mar 2024 11:03

GSK says ViiV's cabotegravir study supports longer HIV dose interval

(Alliance News) - GSK PLC on Tuesday celebrated study results from ViiV Healthcare Ltd, that showed an investigational formulation of cabotegravir can be dosed at four-month intervals.

Read more
5 Mar 2024 07:26

GSK's ViiV upbeat on ultra-long-acting HIV treatment study

(Sharecast News) - GSK announced on Tuesday that its specialist GIV joint venture with Pfizer and Shionogi, ViiV Healthcare, had reported encouraging results from its phase one clinical trial of an investigational formulation of cabotegravir, termed cabotegravir ultra long-acting (CAB-ULA).

Read more
29 Feb 2024 09:44

TOP NEWS: GSK avoids "protracted litigation" with Zantac settlement

(Alliance News) - GSK PLC on Thursday emphasised its commitment to science, as it reached another settlement in ongoing litigation over alleged links between its heartburn drug and cancer.

Read more
29 Feb 2024 07:22

GSK reaches settlement in another Zantac case

(Sharecast News) - GSK announced a confidential settlement with Boyd/Steenvoord, effectively resolving a case filed in California state court over its discontinued heartburn drug Zantac.

Read more
26 Feb 2024 08:25

GSK gonorrhoea treatment achieves efficacy endpoint in latest trial

(Alliance News) - GSK PLC on Monday announced positive results from the latest trial of its oral gonorrhoea treatment, showing it to be on par with intramuscular therapies.

Read more
26 Feb 2024 07:22

GSK reports positive results from gonorrhoea treatment trial

(Sharecast News) - GSK announced encouraging headline outcomes from its trial of gepotidacin, an oral antibiotic aiming to address uncomplicated urogenital gonorrhoea in adolescents and adults, on Monday.

Read more
21 Feb 2024 09:47

GSK reports encouraging results for ViiV's Cabenuva HIV treatment

(Alliance News) - GSK PLC on Wednesday said that its majority-owned company ViiV Healthcare had received positive interim data from ongoing trials of its injectable HIV treatment.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.